Genzyme Reiterates Board's Position on Sanofi-Aventis Tender Offer

Genzyme Corp. today reiterated the unanimous recommendation of its board of directors.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 13, 2010 - Genzyme Corp. (NASDAQ: GENZ) today reiterated the unanimous recommendation of its board of directors that shareholders continue to reject the Sanofi-Aventis $69-per-share tender offer, which has been extended until January 21, 2011.

“The results of the tender offer reported today demonstrate that our shareholders strongly support the view of the board that the Sanofi offer substantially undervalues Genzyme,” said Henri Termeer, Genzyme's chairman and chief executive officer.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, th